Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation.

نویسندگان

  • Aarne Vartia
  • Markku R Asola
  • Risto Tertti
  • Pertti Kunelius
  • Kaj P Metsärinne
چکیده

In the past few years several cases of pure red-cell aplasia (PRCA) associated with neutralizing antierythropoietin antibodies emerging during epoetin treatment have been reported [1–6]. The majority of the cases have occurred in Europe and have been associated with subcutaneous administration of epoetin alfa [4,7,9,10]. There are very few reports from theUSA. The epoetin alfa preparations used in USA are different from those used in Europe [7,10]. Discontinuation of epoetin therapy as well as immunosuppressive treatment have been used to treat the condition. We report two patients who developed PRCA during subcutaneous epoetin alfa therapy. After discontinuation of epoetin alfa, both patients were successfully treated with other epoetins followed by a good response in erythropoiesis and without any signs of allergic reactions.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report

INTRODUCTION Pure red cell aplasia due to anti-epoetin antibodies is a known complication of epoetin therapy for anemia due to chronic kidney disease. This disease has not previously been well described in the setting of therapy for chronic hepatitis C virus infection. While treatment for pure red cell aplasia due to anti-epoetin antibodies is usually with immunosuppressive therapy such as calc...

متن کامل

Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.

Recombinant human erythropoietin (epoetin) was first used for the treatment of renal anaemia in 1986. During the first 10 years of its use, epoetin-induced antibodies were a rare complication and only three cases of patients with epoetin-induced antibodies associated with pure red cell aplasia (PRCA) were published. Since 1998, however, there has been a significant increase in the number of pat...

متن کامل

Pure red cell aplasia after treatment of renal anaemia with epoetin theta

The treatment of renal anaemia in patients with chronic kidney disease (CKD) has always been a challenge. The introduction of erythropoiesis-stimulating agents (ESAs) appeared to be a milestone, enabling physicians to avoid red blood cell transfusions in this patient group. In the last decade, however, these assumed advances were tarnished by the occurrence of a new condition: ESA-induced, anti...

متن کامل

Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis.

Recombinant Human Erythropoietin (EPO) is extensively used for anemia in renal failure patients. It is normally safe and effective, improving symptoms of anemia. We report here a case of renal anemia in a patient undergoing peritoneal dialysis (PD) for end stage renal failure from renovascular disease. He initially responded well to Epoetin alpha (Eprex) but subsequently developed EPO antibodie...

متن کامل

Pure Red Cell Aplasia Induced by Antibodies against Human Recombinant Erythropoietin

Human recombinant erythropoietin (epoetin) is a very effective and safe biopharmaceutical. However, in 1998 the incidence of pure red cell aplasia (PRCA) induced by antierythropoietin (anti-EPO) antibodies in patients treated with epoetin started to increase. PRCA is a rare condition of non-regenerative anemia which can be associated with a variety of diseases and is in some cases of immunologi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

دوره 19 5  شماره 

صفحات  -

تاریخ انتشار 2004